Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 452-458

  Gu, Yifeng ^a   Yang, Peifang ^a,b   Shao, Qing ^a   Liu, Xia ^a,c   Xia, Sheng ^a,c   Zhang, Miaomiao ^a,c   Xu, Huaxi ^a,c   Shao, Qixiang ^a,c  

^a JIANGSU UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^c Zhenjiang Key Laboratory of Medical Diagnosis   (China)

Author keywords

Correlation; DNA methyltransferases; Expression pattern; Histone deacetylases; Ovarian cancer

Indexed keywords

DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; MESSENGER RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84871537487     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1057     Document Type: Article

References (44)

1. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, MaloneJ and Munkarah AR: Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189: 1120-1127, 2003.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
3. Liu CM: Cancer of the ovary. N Engl J Med 352: 1268-1269; author reply 1268-1269, 2005.
4. Kwon MJ and Shin YK: Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci 12: 983-1008, 2011.
5. Li E, Bestor TH and Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915-926, 1992.
6. Li E, Beard C and Jaenisch R: Role for DNA methylation in genomic imprinting. Nature 366: 362-365, 1993.
7. Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257, 1999.
8. Weber M, Hellmann I, Stadler MB, et al: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466, 2007.
9. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
10. Gu W and Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997.
11. Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K and Giacca M: E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275: 10887-10892, 2000.
12. Ammanamanchi S, Freeman JW and Brattain MG: Acetylated sp3 is a transcriptional activator. J Biol Chem 278: 35775-35780, 2003.
13. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and vanKuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 (Pt 3): 737-749, 2003.
14. Gregoretti IV, Lee YM and Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31, 2004.
15. Mizuno S, Chijiwa T, Okamura T, et al: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97: 1172-1179, 2001.
16. Yang B, Guo M, Herman JG and Clark DP: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163: 1101-1107, 2003.
17. Girault I, Tozlu S, Lidereau R and Bièche I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9: 4415-4422, 2003.
18. Ahluwalia A, Hurteau JA, Bigsby RM and Nephew KP: DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 82: 299-304, 2001.
19. Omisanjo OA, Biermann K, Hartmann S, et al: DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. Histochem Cell Biol 127: 175-181, 2007.
20. Weichert W: HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280: 168-176, 2009.
21. Weichert W, Röske A, Gekeler V, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610, 2008.
22. Zhou Q, Agoston AT, Atadja P, Nelson WG and Davidson NE: Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 6: 873-883, 2008.
23. You JS, Kang JK, Lee EK, et al: Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 27: 1376-1386, 2008.
24. Fuks F, Burgers WA, Brehm A, Hughes-Davies L and KouzaridesT: DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24: 88-91, 2000.
25. Boumber Y and Issa JP: Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220-226, 228, 2011.
26. Marks PA: Epigenetic targeted anti-cancer drugs: an unfolding story. Oncology (Williston Park) 25: 231, 235, 2011.
27. Benda JA and Zaino R: GOG Pathology Manual. Buffalo, NY: Gynecologic Oncology Group. 1994.
28. Staging announcement: FIGO cancer committee. Gynecol Oncol 25: 4, 1986.
29. Tsankova N, Renthal W, Kumar A and Nestler EJ: Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8: 355-367, 2007.
30. Halusková J: Epigenetic studies in human diseases. Folia Biol (Praha) 56: 83-96, 2010.
31. Mandrekar P: Epigenetic regulation in alcoholic liver disease. World J Gastroenterol 17: 2456-2464, 2011.
32. Brait M and Sidransky D: Cancer epigenetics: above and beyond. Toxicol Mech Methods 21: 275-288, 2011.
33. Ferguson LR, Tatham AL, Lin Z and Denny WA: Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets 11: 199-212, 2011.
34. Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2: 67, 2011.
35. Maldonado L and Hoque MO: Epigenomics and ovarian carcinoma. Biomark Med 4: 543-570, 2010.
36. Abbas A and Gupta S: The role of histone deacetylases in prostate cancer. Epigenetics 3: 300-309, 2008.
37. Weichert W, Denkert C, Noske A, et al: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10: 1021-1027, 2008.
38. Hayashi A, Horiuchi A, Kikuchi N, et al: Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 127: 1332-1346, 2010.
39. Song J, Noh JH, Lee JH, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268, 2005.
40. Sun L, Hui AM, Kanai Y, Sakamoto M and Hirohashi S: Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res 88: 1165-1170, 1997.
41. Braconi C, Huang N and Patel T: MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51: 881-890, 2010.
42. Wang L, Zou X, Berger AD, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1: 62-71, 2009.
43. Tariq M, Saze H, Probst AV, Lichota J, Habu Y and PaszkowskiJ: Erasure of CpG methylation in Arabidopsis alters patterns of histone H3 methylation in heterochromatin. Proc Natl Acad Sci USA 100: 8823-8827, 2003.
44. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP and Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278: 4035-4040, 2003.